Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
Abstract The SARS-CoV-2 Delta variant is currently the dominant circulating strain in the
world. Uncovering the structural basis of the enhanced transmission and altered immune …
world. Uncovering the structural basis of the enhanced transmission and altered immune …
[HTML][HTML] Recent advances in management of COVID-19: A review
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused and is still causing
significant mortality and economic consequences all over the globe. As of today, there are …
significant mortality and economic consequences all over the globe. As of today, there are …
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma
J Geng, L Chen, Y Yuan, K Wang, Y Wang… - Signal transduction and …, 2021 - nature.com
SARS-CoV-2 mutations contribute to increased viral transmissibility and immune escape,
compromising the effectiveness of existing vaccines and neutralizing antibodies. An in-depth …
compromising the effectiveness of existing vaccines and neutralizing antibodies. An in-depth …
Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
Abstract Monoclonal anti‐SARS‐CoV‐2 immunoglobulins represent a treatment option for
COVID‐19. However, their production in mammalian cells is not scalable to meet the global …
COVID‐19. However, their production in mammalian cells is not scalable to meet the global …
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA. 1, BA. 2, and BA. 4/5 and diverse sarbecoviruses
M Li, Y Ren, ZQ Aw, B Chen, Z Yang, Y Lei… - Nature …, 2022 - nature.com
Abstract As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
Advances in nanomaterial-based platforms to combat COVID-19: Diagnostics, preventions, therapeutics, and vaccine developments
The COVID-19 pandemic caused by the SARS-CoV-2, a ribonucleic acid (RNA) virus that
emerged less than two years ago but has caused nearly 6.1 million deaths to date. Recently …
emerged less than two years ago but has caused nearly 6.1 million deaths to date. Recently …
NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning
T Cohen, M Halfon… - Frontiers in …, 2022 - frontiersin.org
Antibodies are a rapidly growing class of therapeutics. Recently, single domain camelid
VHH antibodies, and their recognition nanobody domain (Nb) appeared as a cost-effective …
VHH antibodies, and their recognition nanobody domain (Nb) appeared as a cost-effective …
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic
antibodies and urgently demands powerful new therapeutics that can resist viral escape. We …
antibodies and urgently demands powerful new therapeutics that can resist viral escape. We …